Table 4.

APOL1 risk allele associations with HIVAN, HIV-associated FSGS, and HIV-negative FSGS (primary FSGS)

No. of Risk AllelesHIV-Positive CKD Patient Groups (n=51) versus HIV-Positive Controls (n=54)Primary FSGS (n=9) versus Population Controls (n=54)All FSGS (n=22) versus All Controls (n=108)
HIVAN (n=38)HIV-Positive FSGS (n=13)Primary FSGS (n=9)HIV-Positive FSGS (n=13) and Primary FSGS (n=9)
OR (95% CI)P ValueAdjusted P ValueaOR (95% CI)P ValueOR (95% CI)P ValueOR (95% CI)P Value
1 versus 05.49 (0.87 to 61.14)0.050.130.63 (0.10 to 2.98)0.741.3 (0.18 to 7.42)>0.990.86 (0.25 to 2.64)>0.99
2 versus 0200.87 (27.62 to 3119.17)1.5×10−141.9×10−31.85 (0.03 to 39.57)0.536.70 (0.08 to 577.00)0.263.27 (0.25 to 31.46)0.22
2 versus 140.50 (7.09 to 446.94)8.7×10−081.8×10−42.82 (0.04 to 73.20)0.445.0 (0.05 to 467.90)0.343.74 (0.26 to 40.67)0.20
2 versus 1 or 0 recessive model89.1 (17.68 to 911.72)1.2×10−141.5×10−52.13 (0.03 to 44.30)0.486.30 (0.04 to 248.70)0.263.45 (0.27 to 32.23)0.20
  • ORs (95% CIs) are shown for the association between APOL1 risk alleles and particular glomerular diseases. P values are from Fisher’s exact test unless otherwise noted.

  • a Analyses were adjusted for age, sex, and ancestry.